<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html lang="en">

<head>
  <title>Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes - Full Text View - ClinicalTrials.gov</title>
    <meta name="robots" content="noindex,nofollow"/>
    <meta http-equiv="Content-Type" content="text/html;charset=UTF-8"/>
    <link href="/ct2/show/NCT00174993" rel="canonical"/>
    <link href="/ct2/html/images/frame/icon.ico" rel="SHORTCUT ICON"/>
  <link href="/ct2/html/images/frame/ct.css" type="text/css" rel="stylesheet"/>
  <script type="text/javascript" src="/ct2/html/images/frame/ct.js" language="JavaScript">
  </script>
</head>

<body style="min-width:720px; margin-left:0px; margin-right:0px; margin-top:0px" onload="doLoadActions();">

<!-- small_banner -->
<div class="skip"><a href="#MainContent">Skip to Main Content</a></div>

<table class="layout_table banner_color" cellspacing="0" cellpadding="0" border="0" width="100%">
  <tr>
    <td align="left" style="padding:6px" nowrap>
      <a title="Show Home Page" href="/ct2/home">
        <img alt="ClinicalTrials.gov" src="/ct2/html/images/frame/small_title.gif" border="0"/>
      </a>
    </td>

    <td class="header3" align="right" style="padding:3px 12px 3px 3px;" nowrap>
            <a style="margin-left:1em;" title="Show Home Page" href="/ct2/home">Home</a>
            <a style="margin-left:1em;" title="Show Search Page" href="/ct2/search">Search</a>
            <a style="margin-left:1em;" title="Show Study Topics Page" href="/ct2/search/browse">Study Topics</a>
            <a style="margin-left:1em;" title="Show Glossary Page" href="/ct2/info/glossary">Glossary</a>
            <br/>
      <form method="get" action="/ct2/results" style="margin-top:0.5ex; margin-bottom:0px;">
        <input class="body3" type="text" name="term" alt="Quick Search" title="Quick Search" value="" size="30" maxlength="250"/>
        <input class="header3" type="submit" alt="Search" value="Search"/>
        
      </form>
    </td>
  </tr>
</table>

<img width="100%" height="3" src="/ct2/html/images/frame/bar.gif" alt=""/><br/>

<a name="MainContent" id="skipnav"></a>


<!-- above_tabs -->
<div class="show_back_color">
<br/>


</div>








<!-- tabs -->
<div class="show_back_color header3">
<table class="layout_table" cellpadding="0" cellspacing="0" border="0">
  <tr valign="bottom">
            <td valign="bottom"><img style="width:20px; height:2px" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="fore_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_fore.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_fore.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:4ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5ex 1.0em" nowrap >
            <span class="header2">Full Text View</span>
          </td>
          <td align="right"><img style="width:2px; height:4ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img width="1" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td/>
          <td align="right"><img width="2" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="back_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_back.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_back.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5px 0.5em" nowrap>
            <a title="Show Tabular View Page" href="/ct2/show/record/NCT00174993" >Tabular View</a>
          </td>
          <td align="right"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td valign="top" colspan="3"><img width="100%" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="back_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_back.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_back.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5px 0.5em" nowrap>
            <a title="Show No Study Results Posted Page" href="/ct2/show/results/NCT00174993"  style="color:#666666" >No Study Results Posted</a>
          </td>
          <td align="right"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td valign="top" colspan="3"><img width="100%" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td valign="bottom"><img style="width:50px; height:2px" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="back_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_back.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_back.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5px 0.5em" nowrap>
            <a title="Show Related Studies Page" href="/ct2/show/related/NCT00174993" >Related Studies</a>
          </td>
          <td align="right"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td valign="top" colspan="3"><img width="100%" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        <td valign="bottom" width="100%"><img style="width:100%; height:2px" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
  </tr>
</table>
</div>

<!-- Title section -->
<div class="indent3" align="center">

    <div class="header1" style="margin-top:3ex;">Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes (PROactive)</div>
  
      <div class="header2" style="margin-top:2ex; color:  red  ">
    This study has been completed.
  </div>
      
  
  <div style="margin-top:2ex">
    First Received: September 9, 2005 &nbsp;
          Last Updated: August 3, 2009 &nbsp;
      <a href="/ct2/archive/NCT00174993"
        title="Historical versions of study NCT00174993 on ClinicalTrials.gov Archive Site"
        onclick="openNewWindow('/ct2/archive/NCT00174993'); return false;">History of Changes</a>
      </div>

  <table class="data_table" cellspacing="0" cellpadding="5" border="1" width="50%" style="margin:2ex 0;">

        <tr>
      <th align="right" nowrap class="header3 pale_banner_color"> Sponsor: </th>
      <td align="left" nowrap class="body2"> Takeda Global Research &amp; Development Centre (Europe) Ltd. </td>
    </tr>
    
        <tr>
      <th align="right" nowrap class="header3 pale_banner_color">
         Collaborator:       </th>
      <td align="left" nowrap class="body2">
                                         Eli Lilly and Company<br/>               </td>
    </tr>
    
        <tr>
      <th align="right" nowrap class="header3 pale_banner_color">Information provided by: </th>
      <td align="left" nowrap class="body2">Takeda Global Research &amp; Development Center, Inc.</td>
    </tr>
    
    <tr>
      <th align="right" nowrap class="header3 pale_banner_color">ClinicalTrials.gov Identifier: </th>
      <td align="left" nowrap class="body2">NCT00174993</td>
    </tr>

  </table>

</div>
  
<!-- purpose_section -->
<div class="indent1" style="margin-top:3ex">
<img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; Purpose</span>

<div class="indent2" style="margin-top:2ex">

  <div class="body3"><p style="margin-bottom:1ex;">The purpose of this study is to determine whether pioglitazone can delay the time to death, heart attack, acute coronary syndrome, heart bypass surgery, stroke, leg bypass surgery or amputation in patients with type 2 diabetes.</p></div><br/>

    <!-- condition, intervention, phase summary table -->
  <div align="center">
  <table class="data_table" cellspacing="0" cellpadding="5" border="1" width="80%">
    <tr align="left">
            <th class="header3 pale_banner_color">
        <a href="/ct2/help/conditions_desc" title="Help on Conditions field" onclick="openPopupWindow('/ct2/help/conditions_desc',false); return false;">Condition</a>
      </th>
                  <th class="header3 pale_banner_color">
        <a href="/ct2/help/interventions_desc" title="Help on Interventions field" onclick="openPopupWindow('/ct2/help/interventions_desc',false); return false;">Intervention</a>
      </th>
                  <th class="header3 pale_banner_color">
        <a href="/ct2/help/phase_desc" title="Help on Phase field" onclick="openPopupWindow('/ct2/help/phase_desc',false); return false;">Phase</a>
      </th>
          </tr>
    <tr align="left" valign="top">
            <td class="body3" nowrap>
                Diabetes Mellitus<br/>
              </td>
                  <td class="body3" nowrap>
                Drug: Pioglitazone<br/>
                Drug: Placebo<br/>
              </td>
                  <td class="body3" nowrap>
                Phase III<br/>
              </td>
          </tr>
  </table>
  </div>
  <br/>
  
  <table class="layout_table" style="margin-bottom:2ex;" cellpadding="0" cellspacing="0" border="0">
        <tr valign="top">
      <td nowrap>Study Type:</td>
      <td style="padding-left:1em">Interventional</td>
    </tr>
            <tr valign="top">
      <td nowrap>Study Design:</td>
      <td style="padding-left:1em">Allocation:&#160;Randomized<br/>Control:&#160;Placebo&#160;Control<br/>Endpoint&#160;Classification:&#160;Safety&#160;Study<br/>Intervention&#160;Model:&#160;Parallel&#160;Assignment<br/>Masking:&#160;Double&#160;Blind&#160;(Subject,&#160;Caregiver,&#160;Investigator,&#160;Outcomes&#160;Assessor)<br/>Primary&#160;Purpose:&#160;Treatment</td>
    </tr>
            <tr valign="top">
      <td nowrap style="padding-top:2ex">Official Title:</td>
      <td style="padding-left:1em; padding-top:2ex">PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy</td>
    </tr>
      </table>

    <!-- NLM links -->
  <br/>
  <div class="header3">Resource links provided by NLM:</div>
  <br/>
  <div class="indent3">

  
    <!-- medline links -->
  <div style="margin-bottom:2ex;">
    <a href="http://www.nlm.nih.gov/medlineplus/" title="MedlinePlus site" onclick="openNewWindow('http://www.nlm.nih.gov/medlineplus/'); return false">MedlinePlus</a> related topics:
            <a style="padding-left:0.5em;" href="/ct2/bye/4QoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS90d-yZdNGST7GSihHST7yxwhGFw-gLwNizwU5uQoPmdt." title="Coronary&#160;Artery&#160;Bypass&#160;Surgery at MedlinePlus site" onclick="openNewWindow('/ct2/bye/4QoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS90d-yZdNGST7GSihHST7yxwhGFw-gLwNizwU5uQoPmdt.'); return false">Coronary&#160;Artery&#160;Bypass&#160;Surgery</a>
                <a style="padding-left:0.5em;" href="/ct2/bye/EQoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS95Q7Gp61PzwSxlihLv." title="Diabetes at MedlinePlus site" onclick="openNewWindow('/ct2/bye/EQoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS95Q7Gp61PzwSxlihLv.'); return false">Diabetes</a>
                <a style="padding-left:0.5em;" href="/ct2/bye/FQoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS9l67GSihGWihG0QSxlihLv." title="Heart&#160;Attack at MedlinePlus site" onclick="openNewWindow('/ct2/bye/FQoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS9l67GSihGWihG0QSxlihLv.'); return false">Heart&#160;Attack</a>
                <a style="padding-left:0.5em;" href="/ct2/bye/ZQoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS9Fi1yU61yxXNkWd7E." title="Surgery at MedlinePlus site" onclick="openNewWindow('/ct2/bye/ZQoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS9Fi1yU61yxXNkWd7E.'); return false">Surgery</a>
          </div>
  
    <!-- SIS links -->
  <div style="margin-bottom:2ex;">
    <a href="http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp" title="Drug Information Portal" onclick="openNewWindow('http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp'); return false">Drug Information</a> available for:
            <a style="padding-left:0.5em;" href="/ct2/bye/GQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd7898hzZ6caeihGrdcxz." title="Pioglitazone at ChemIDplus site" onclick="openNewWindow('/ct2/bye/GQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd7898hzZ6caeihGrdcxz.'); return false">Pioglitazone</a>
                <a style="padding-left:0.5em;" href="/ct2/bye/CQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd7898hzZ6caeihGrdcxzIckx6oyZBckvd-ye6h8." title="Pioglitazone&#160;hydrochloride at ChemIDplus site" onclick="openNewWindow('/ct2/bye/CQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd7898hzZ6caeihGrdcxzIckx6oyZBckvd-ye6h8.'); return false">Pioglitazone&#160;hydrochloride</a>
          </div>
  
  <div style="margin-bottom:2ex;">
    <a href="/ct2/info/fdalinks" title="Show FDA resources page" onclick="openNewWindow('/ct2/info/fdalinks'); return false">U.S. FDA Resources</a>
  </div>

  </div>
  
    <!-- more details -->
  <br/>
  <div class="header3">Further study details as provided by Takeda Global Research &amp; Development Center, Inc.:</div>
  <br/>
  <div class="indent3">

        <!-- primary outcomes -->
    <div class="body3">Primary Outcome Measures:
      <ul style="margin-top:1ex; margin-bottom:1ex;">
            <li style="margin-top:0.7ex;">Time to the Composite of All Cause Mortality, Non-Fatal Myocardial Infarction, Stroke, Acute Coronary Syndrome, Major Leg Amputation, Cardiac Intervention, Bypass Surgery or Leg Revascularization. [&nbsp;Time&nbsp;Frame:&nbsp;At First Occurrence&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<br/>
            </ul>
    </div>
    <br/>
    
        <!-- secondary outcomes -->
    <div class="body3">Secondary Outcome Measures:
      <ul style="margin-top:1ex; margin-bottom:1ex;">
            <li style="margin-top:0.7ex;">Time to All Cause Mortality. [&nbsp;Time&nbsp;Frame:&nbsp;At occurrence&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Time to Non-Fatal Myocardial Infarction. [&nbsp;Time&nbsp;Frame:&nbsp;At occurrence&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Time to Acute Coronary Syndrome. [&nbsp;Time&nbsp;Frame:&nbsp;At occurrence&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Time to Cardiac Intervention (including coronary artery bypass graft or percutaneous coronary intervention). [&nbsp;Time&nbsp;Frame:&nbsp;At occurrence&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Time to Stroke. [&nbsp;Time&nbsp;Frame:&nbsp;At occurrence&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Time to Major Leg Amputation (above the ankle). [&nbsp;Time&nbsp;Frame:&nbsp;At occurrence&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Time to Bypass Surgery [&nbsp;Time&nbsp;Frame:&nbsp;At occurrence&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Time to Revascularization of the Leg. [&nbsp;Time&nbsp;Frame:&nbsp;At occurrence&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Time to Cardiovascular Mortality. [&nbsp;Time&nbsp;Frame:&nbsp;At occurrence&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<br/>
            </ul>
    </div>
    <br/>
    
    
    
    <table class="layout_table" style="margin-bottom:3ex;" cellpadding="0" cellspacing="0" border="0">
            <tr valign="top">
        <td nowrap> Enrollment:</td>
        <td style="padding-left:1em">4373</td>
      </tr>
                  <tr valign="top">
        <td nowrap> Study Start Date:</td>
        <td style="padding-left:1em">May 2001</td>
      </tr>
                  <tr valign="top">
        <td nowrap> Study Completion Date:</td>
        <td style="padding-left:1em">January 2005</td>
      </tr>
                  <tr valign="top">
        <td nowrap> Primary Completion Date:</td>
        <td style="padding-left:1em">January 2005 (Final data collection date for primary outcome measure)</td>
      </tr>
          </table>

        <!-- arms and groups table -->
    <div align="center">
    <table class="data_table" cellspacing="0" cellpadding="5" border="1" width="100%">
      <tr align="left">
        <th class="header3 pale_banner_color">
          <a href="/ct2/help/arm_group_desc" title="Help on Arm Group field" onclick="openPopupWindow('/ct2/help/arm_group_desc',false); return false;">
             Arms           </a>
        </th>
                <th class="header3 pale_banner_color">
          <a href="/ct2/help/interventions_desc" title="Help on Interventions field" onclick="openPopupWindow('/ct2/help/interventions_desc',false); return false;">
            Assigned Interventions
          </a>
        </th>
              </tr>
            <tr align="left" valign="top">
        <td class="body3">
          1: Experimental
                  </td>
                <td class="body3">
                    Drug: Pioglitazone
                    <div style="margin:0.5ex; margin-left:4ex">
          Pioglitazone 15 mg to 45 mg, tablets, orally, once daily for up to 48 months.
          </div>
                            </td>
              </tr>
            <tr align="left" valign="top">
        <td class="body3">
          2: Placebo Comparator
                  </td>
                <td class="body3">
                    Drug: Placebo
                    <div style="margin:0.5ex; margin-left:4ex">
          Pioglitazone placebo-matching tablets, orally, once daily for up to 48 months
          </div>
                            </td>
              </tr>
          </table>
    </div>
    <br/>
    
    
    <a name="desc" id="desc"></a>

    
    
        <!-- detailed description -->
    <span class="header3">Detailed Description:</span>
    <div class="body3"><p style="margin-bottom:1ex;">Diabetes mellitus is one of the most common non-communicable diseases worldwide. More than 22 million persons have been diagnosed with diabetes in the European region of the International Diabetes Federation. Complications of diabetes involving both microvascular and macrovascular systems contribute to increased disability and reduced life expectancy. Damage to the coronary, cerebral (brain), and peripheral vascular beds as a consequence of diabetes is responsible for the increased macrovascular illness and death associated with the disease.</p>
<p style="margin-bottom:1ex;">Insulin resistance is common to the genesis of both atherosclerosis and type 2 diabetes mellitus. In diabetes, insulin resistance is coupled to receptor dysfunction. In atherosclerosis, insulin resistance may have both direct effects on the cardiovascular system as well as indirect effects provoked by imbalances in blood glucose, lipids, clotting factors, endothelial function, and other factors. Considerable indirect evidence suggests that peroxisome proliferator-activated receptor agonists may favorably influence macrovascular outcome, either through modification of risk factors (such as blood lipids) or through effects on the vessel wall.</p>
<p style="margin-bottom:1ex;">Pioglitazone, a thiazolidinedione compound discovered by Takeda Pharmaceutical Company, Ltd, functions as a peroxisome proliferator-activated receptor agonist as its mode of action.</p>
<p style="margin-bottom:1ex;">This study is designed to assess whether pioglitazone in combination with other medications administered for glycemic management of type 2 diabetes might reduce the incidence of macrovascular events associated with this disease compared with placebo. Individuals who participate in this study will provide written informed consent and will be required to commit to screening and randomization visits and approximately 17 additional visits (1 every 2 months for the first year and every 3 months thereafter) at the study center. Study participation is anticipated to be about 40 months (or approximately 3 years and 4 months). Multiple procedures will occur at each visit which may include fasting, blood collection, physical examinations and electrocardiograms.</p></div>
        
  </div>
  
</div>
</div>
  
<!-- eligibility_section -->
<div class="indent1" style="margin-top:3ex; border:1px solid white">
  <img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; Eligibility</span><br/>

  <br/>
  <div class="indent2">
    <table class="layout_table" cellpadding="0" cellspacing="0" border="0">
            <tr>
        <td nowrap>Ages Eligible for Study: &nbsp; </td>
        <td style="padding-left:1em">35 Years to 75 Years</td>
      </tr>
                  <tr>
        <td nowrap>Genders Eligible for Study: &nbsp; </td>
        <td style="padding-left:1em">Both</td>
      </tr>
                  <tr>
        <td nowrap>Accepts Healthy Volunteers: &nbsp; </td>
        <td style="padding-left:1em">No</td>
      </tr>
                </table>

    
        <div class="header3" style="margin-top:2ex">Criteria</div>
    <div class="indent2"><p style="margin-bottom:1ex;">Inclusion Criteria</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Type 2 diabetes mellitus</li>
<li style="margin-top:0.7ex;">Glycosylated hemoglobin above the upper limit of normal (ie, the local equivalent of 6.5% for)</li>
<li style="margin-top:0.7ex;"><p style="margin-bottom:1ex;">Established history of macrovascular disease, defined as 1 or more of:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Myocardial infarction at least 6 months before entry into the study.</li>
<li style="margin-top:0.7ex;">Stroke at least 6 months before entry into the study</li>
<li style="margin-top:0.7ex;">Percutaneous coronary intervention or coronary artery bypass graft at least 6 months before entry into the study.</li>
<li style="margin-top:0.7ex;">Acute coronary syndrome at least 3 months before entry into the study.</li>
<li style="margin-top:0.7ex;">Objective evidence of coronary artery disease.</li>
<li style="margin-top:0.7ex;">Peripheral arterial obstructive disease</li>
</ul>
</li>
</ul>
<p style="margin-bottom:1ex;">Exclusion Criteria</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Signs of type 1 diabetes.</li>
<li style="margin-top:0.7ex;">Patients prescribed insulin as sole therapy for glycemic control of diabetes for 2 weeks or more at any time in the previous 3 months.</li>
<li style="margin-top:0.7ex;">Myocardial infarction, stroke, coronary artery bypass graft, or percutaneous cardiac intervention in the 6 months prior to enrolment.</li>
<li style="margin-top:0.7ex;">Acute coronary syndrome in the 3 months prior to enrolment.</li>
<li style="margin-top:0.7ex;">Heart failure at entry defined as patient having a New York Heart Association functional score of II or above.</li>
<li style="margin-top:0.7ex;">Had an appointment for a coronary angiogram or endovascular or surgical intervention.</li>
<li style="margin-top:0.7ex;">Leg ulcers, gangrene, or ischemic rest pain.</li>
<li style="margin-top:0.7ex;">Had an appointment for an angiogram or endovascular or surgical intervention for leg ischemia.</li>
<li style="margin-top:0.7ex;">Had undergone a major operation (defined as a surgical procedure lasting for more than 30 minutes) at any time in the previous 4 weeks.</li>
<li style="margin-top:0.7ex;">Significantly impaired hepatic function, defined as alanine aminotransferase greater than 2.5 times the upper limit of normal.</li>
<li style="margin-top:0.7ex;">Familial polyposis coli.</li>
<li style="margin-top:0.7ex;">Required dialysis.</li>
<li style="margin-top:0.7ex;">History of alcohol or drug abuse.</li>
<li style="margin-top:0.7ex;">Any other intercurrent disease believed to be likely to have a significant impact on the patient's life expectancy during the course of the study (eg, cancer).</li>
<li style="margin-top:0.7ex;">Patient was undergoing follow-up as part of another clinical trial or less than 3 months had elapsed since the last dose of an investigational drug or procedure.</li>
<li style="margin-top:0.7ex;">Hypersensitivity to pioglitazone or other TZD.</li>
<li style="margin-top:0.7ex;">Current use of pioglitazone or other TZD.</li>
<li style="margin-top:0.7ex;">Patient was known to be infected with human immunodeficiency virus or was known to have viral hepatitis.</li>
<li style="margin-top:0.7ex;">Women who were any of the following: pregnant, breast feeding, wished to become pregnant during the course of the study or of childbearing potential and not planning to use a reliable method of contraception throughout the study.</li>
</ul></div>
    
  </div>

</div>

  
<!-- location_section -->
<div class="indent1" style="margin-top:3ex">
<img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; Contacts and Locations</span><br/>

<div class="indent2" style="margin-top:2ex">

    Please refer to this study by its ClinicalTrials.gov identifier: NCT00174993<br/>
  <br/>

  <!-- contacts -->
  
  <!-- locations -->
  <a name="locn" id="locn"></a>

    <img style="float:left" border="0" src="/ct2/html/images/frame/plus.gif" alt=""/>&nbsp;
  <a class="header3" title="Show 19 study locations" href="/ct2/show/study/NCT00174993?show_locs=Y#locn">Show 19 Study Locations</a><br/>

  
  <!-- sponsors -->
    <div class="header3" style="margin-top:2ex">Sponsors and Collaborators</div>
    <div class="indent2" style="margin-top:1ex">Takeda Global Research &amp; Development Centre (Europe) Ltd.</div>
    <div class="indent2" style="margin-top:1ex">Eli Lilly and Company</div>
    
  <!-- investigators -->
    <div class="header3" style="margin-top:2ex">Investigators</div>
  <table class="layout_table indent2" cellspacing="0" cellpadding="0" border="0">
        <tr>
      <td style="padding:1ex 1em 0px 0px" nowrap>Study Director:</td>
      <td style="padding:1ex 1em 0px 0px" nowrap>European Development Director</td>
            <td style="padding:1ex 1em 0px 0px" nowrap>Takeda Global Research &amp; Development Centre (Europe) Ltd.</td>
                </tr>
      </table>
  

</div>
</div>

<!-- more_info_section -->
<div class="indent1" style="margin-top:3ex; border:1px solid white">
<img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; More Information</span>

<div class="indent2">
  <br/>

    Additional Information:
    <div class="indent2" style="margin-top:2ex">
        <a href="/ct2/bye/qQoPWw4lZXcizdNHSB7EuihGf67PkwhkkwNWuBc9mXcgZdUPzdUVZ6Nzv6D9EQDxE6hBAB13Edhz0B1Pedcx0dcPzs7GpRNV-RCjSXCkzB0Rmg4BLBDWO6NPkXCRLR4jOBCzzB76pRY6NQ7azHozE68gZ6h89V8g8CLgVDV/8V8g8CLRJ8hG0QcGU6D3ydUgzwUV" title="ACTOS Package Insert" onclick="openNewWindow('/ct2/bye/qQoPWw4lZXcizdNHSB7EuihGf67PkwhkkwNWuBc9mXcgZdUPzdUVZ6Nzv6D9EQDxE6hBAB13Edhz0B1Pedcx0dcPzs7GpRNV-RCjSXCkzB0Rmg4BLBDWO6NPkXCRLR4jOBCzzB76pRY6NQ7azHozE68gZ6h89V8g8CLgVDV/8V8g8CLRJ8hG0QcGU6D3ydUgzwUV'); return false">ACTOS Package Insert</a>&nbsp
    <img src="/ct2/html/images/frame/exit.bmp" alt="This link exits the ClinicalTrials.gov site"/>
      </div>
    <div class="indent2" style="margin-top:2ex">
        <a href="/ct2/bye/NQoPWw4lZX-i-iSxN6hju6c9cXWLGPGi3HjgnX-gk6NHWTDxlihW/iP5P3nGgk6NHWTD33dhHSioRJB7x5nGyzBcGvdoR" title="FDA Safety Alerts and Recalls" onclick="openNewWindow('/ct2/bye/NQoPWw4lZX-i-iSxN6hju6c9cXWLGPGi3HjgnX-gk6NHWTDxlihW/iP5P3nGgk6NHWTD33dhHSioRJB7x5nGyzBcGvdoR'); return false">FDA Safety Alerts and Recalls</a>&nbsp
    <img src="/ct2/html/images/frame/exit.bmp" alt="This link exits the ClinicalTrials.gov site"/>
      </div>
    <br/>
  
    Publications:
  <div class="indent2">
            <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCBSRCVLKCJ." title="Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005 Oct 8;366(9493):1279-89." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCBSRCVLKCJ.'); return false">Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005 Oct 8;366(9493):1279-89.</a>
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCJEgCwSRC8." title="Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol. 2008 Jan;19(1):182-7. Epub 2007 Dec 5." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCJEgCwSRC8.'); return false">Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol. 2008 Jan;19(1):182-7. Epub 2007 Dec 5.</a>
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwSg4tSK4n." title="Ryd&#233;n L, Thr&#225;insd&#243;ttir I, Swedberg K. Adjudication of serious heart failure in patients from PROactive. Lancet. 2007 Jan 20;369(9557):189-90. No abstract available." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwSg4tSK4n.'); return false">Ryd&#233;n L, Thr&#225;insd&#243;ttir I, Swedberg K. Adjudication of serious heart failure in patients from PROactive. Lancet. 2007 Jan 20;369(9557):189-90. No abstract available.</a>
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwxg05Fg08." title="Erdmann E, Dormandy J, Wilcox R, Massi-Benedetti M, Charbonnel B. PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study. Vasc Health Risk Manag. 2007;3(4):355-70. Review." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwxg05Fg08.'); return false">Erdmann E, Dormandy J, Wilcox R, Massi-Benedetti M, Charbonnel B. PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study. Vasc Health Risk Manag. 2007;3(4):355-70. Review.</a>
          </div>
        <div style="margin-top:2ex">
            Erdmann E, Dormandy JA. The Effect of Pioglitazone on Recurrent Myocardial Infarction in 2445 Patients with Type 2 Diabetes and Preexisting Myocardial Infarction - Data from the PROactive Study. Circulation 2005;112:(21):3364-3364
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwWg0BSR0w." title="Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007 May 1;49(17):1772-80. Epub 2007 Apr 16." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwWg0BSR0w.'); return false">Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007 May 1;49(17):1772-80. Epub 2007 Apr 16.</a>
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwLKCRSg48." title="Valentine WJ, Bottomley JM, Palmer AJ, Br&#228;ndle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M; PROactive Study Group. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. Diabet Med. 2007 Sep;24(9):982-1002. Epub 2007 Jun 25." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwLKCRSg48.'); return false">Valentine WJ, Bottomley JM, Palmer AJ, Br&#228;ndle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M; PROactive Study Group. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. Diabet Med. 2007 Sep;24(9):982-1002. Epub 2007 Jun 25.</a>
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwSKCtER05." title="Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J; PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007 Mar;38(3):865-73. Epub 2007 Feb 8." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwSKCtER05.'); return false">Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J; PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007 Mar;38(3):865-73. Epub 2007 Feb 8.</a>
          </div>
        <div style="margin-top:2ex">
            Bottomley JM, Palmer AJ, Williams R, Dormandy JA, Massi-Benedetti M. PROactive 03: Pioglitazone, type 2 diabetes and reducing macrovascular events - economic implications?. Br J Diabetes Vasc Dis 2006;6(Pt 2):64-69
          </div>
        <div style="margin-top:2ex">
            Kirby M, Heart Disease Prevention-what place for the glitazones?. Br J Cardiol 2006;13(Pt 1):66-70
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwcg0BWg0n." title="Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA; PROactive investigators. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007 Nov;30(11):2773-8. Epub 2007 Jul 31." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwcg0BWg0n.'); return false">Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA; PROactive investigators. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007 Nov;30(11):2773-8. Epub 2007 Jul 31.</a>
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCJcgCwaR4V." title="Valentine WJ, Tucker D, Palmer AJ, Minshall ME, Foos V, Silberman C. Long-Term Cost-Effectiveness of Pioglitazone versus Placebo in Addition to Existing Diabetes Treatment: A US Analysis Based on PROactive. Value Health. 2008 Jul 24; [Epub ahead of print]" onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCJcgCwaR4V.'); return false">Valentine WJ, Tucker D, Palmer AJ, Minshall ME, Foos V, Silberman C. Long-Term Cost-Effectiveness of Pioglitazone versus Placebo in Addition to Existing Diabetes Treatment: A US Analysis Based on PROactive. Value Health. 2008 Jul 24; [Epub ahead of print]</a>
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCJFgFjWK4j." title="Wilcox R, Kupfer S, Erdmann E; PROactive Study investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J. 2008 Apr;155(4):712-7. Epub 2008 Feb 21. Erratum in: Am Heart J. 2008 Aug;156(2):255." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCJFgFjWK4j.'); return false">Wilcox R, Kupfer S, Erdmann E; PROactive Study investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J. 2008 Apr;155(4):712-7. Epub 2008 Feb 21. Erratum in: Am Heart J. 2008 Aug;156(2):255.</a>
          </div>
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RC8SR0tSg4j." title="Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A; PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care. 2004 Jul;27(7):1647-53." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RC8SR0tSg4j.'); return false">Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A; PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care. 2004 Jul;27(7):1647-53.</a>
          </div>
        <div style="margin-top:2ex">
            Spanheimer,RG, Betteridge,DJOHN, Tan,MH, Ferrannini,E, Charbonnel,B, Long-Term Lipid Effects of Pioglitazone by Baseline Anti-Hyperglycemia Medication Therapy and Statin Use from the PROactive Experience (PROactive 14). Am J Cardiol 2009;104:(2):234-239.
          </div>
              </div>
  <br/>
  
    Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):
  <div class="indent2">
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RC5LgFBFgCR." title="Spanheimer R, Betteridge DJ, Tan MH, Ferrannini E, Charbonnel B; PROactive Investigators. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14). Am J Cardiol. 2009 Jul 15;104(2):234-9. Epub 2009 Jun 3." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RC5LgFBFgCR.'); return false">Spanheimer R, Betteridge DJ, Tan MH, Ferrannini E, Charbonnel B; PROactive Investigators. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14). Am J Cardiol. 2009 Jul 15;104(2):234-9. Epub 2009 Jun 3.</a>
          </div>
      </div>
  <br/>
  
  
  <table class="layout_table" style="margin-top:1ex" cellpadding="0" cellspacing="0" border="0">
        <tr valign="top">
      <td nowrap>Responsible Party:</td>
      <td style="padding-left:1em">Takeda Global Research &amp; Development Centre (Europe) Ltd. ( VP, Clinical Science )</td>
    </tr>
            <tr valign="top">
      <td nowrap>Study ID Numbers:</td>
      <td style="padding-left:1em">AD4833/EC444</td>
    </tr>
            <tr valign="top">
      <td nowrap>Study First Received:</td>
      <td style="padding-left:1em">September 9, 2005</td>
    </tr>
                <tr valign="top">
      <td nowrap>Last Updated:</td>
      <td style="padding-left:1em">August 3, 2009</td>
    </tr>
        <tr valign="top">
      <td nowrap>ClinicalTrials.gov Identifier:</td>
      <td style="padding-left:1em">
        <a title="Current version of study NCT00174993 on ClinicalTrials.gov" href="http://clinicaltrials.gov/ct2/show/NCT00174993">NCT00174993</a> &nbsp; &nbsp;
        <a href="/ct2/archive/NCT00174993"
          title="Historical versions of study NCT00174993 on ClinicalTrials.gov Archive Site"
          onclick="openNewWindow('/ct2/archive/NCT00174993'); return false;">History of Changes</a>
      </td>
    </tr>
        <tr valign="top">
      <td nowrap>Health Authority:</td>
      <td style="padding-left:1em">United Kingdom: Medicines and Healthcare Products Regulatory Agency; &nbsp; France: Afssaps - French Health Products Safety Agency; &nbsp; Germany: Federal Institute for Drugs and Medical Devices; &nbsp; Italy: The Italian Medicines Agency; &nbsp; Austria: Federal Ministry for Health and Women; &nbsp; Switzerland: Swissmedic; &nbsp; Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment; &nbsp; Denmark: Danish Medicines Agency; &nbsp; Sweden: Medical Products Agency; &nbsp; Finland: Finnish Medicines Agency; &nbsp; Norway: Norwegian Medicines Agency; &nbsp; Netherlands: Medicines Evaluation Board (MEB); &nbsp; Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products; &nbsp; Hungary: National Institute of Pharmacy; &nbsp; Slovakia: State Institute for Drug Control; &nbsp; Czech Republic: State Institute for Drug Control; &nbsp; Latvia: State Agency of Medicines; &nbsp; Lithuania: State Medicine Control Agency - Ministry of Health; &nbsp; Estonia: The State Agency of Medicine</td>
    </tr>
      </table>

  
  <!-- keywords -->
    <br/>
  Keywords provided by Takeda Global Research &amp; Development Center, Inc.:
  <div class="indent3">
    <table class="layout_table" cellpadding="0" cellspacing="0" border="0" width="100%">
      <tr valign="top">
        <td width="50%">
                    Glucose Metabolism Disorder<br/>
                    Dysmetabolic Syndrome<br/>
                    Type II Diabetes; Diabetes Mellitus<br/>
                  </td>
                <td width="50%" style="padding-left:1em">
                    Lipoatrophic<br/>
                    Dyslipidemia<br/>
                    Drug Therapy<br/>
                  </td>
              </tr>
    </table>
  </div>
  
  <!-- mesh terms -->
    <br/>
  Additional relevant MeSH terms:
  <div class="indent3">
    <table class="layout_table" cellpadding="0" cellspacing="0" border="0" width="100%">
      <tr valign="top">
        <td width="50%">
                    Hypoglycemic Agents<br/>
                    Metabolic Diseases<br/>
                    Pioglitazone<br/>
                    Physiological Effects of Drugs<br/>
                  </td>
                <td width="50%" style="padding-left:1em">
                    Diabetes Mellitus<br/>
                    Endocrine System Diseases<br/>
                    Glucose Metabolism Disorders<br/>
                    Pharmacologic Actions<br/>
                  </td>
              </tr>
    </table>
  </div>
  
  
  <br/>

    <span class="body3">ClinicalTrials.gov processed this record on April 01, 2010</span><br/>
  
  <br/>

</div>
</div>


<!-- Footer -->
<div class="skip"><a href="#MainContent">Back to top of Main Content</a></div>

<img width="100%" height="3" src="/ct2/html/images/frame/bar.gif" alt=""/><br/>

<div align="center" class="footer">
  <br/>
  <a href="/ct2/helpdesk?hd_url=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2Fnct00174993" onclick="openPopupWindow('/ct2/helpdesk?hd_url=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2Fnct00174993',true); return false;">Contact Help Desk</a><br/>
  <a href="http://www.lhncbc.nlm.nih.gov">Lister Hill National Center for Biomedical Communications</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/">U.S. National Library of Medicine</a>,<br/>
  <a href="http://www.nih.gov/">U.S. National Institutes of Health</a>,&nbsp;
  <a href="http://www.os.dhhs.gov/">U.S. Department of Health &amp; Human Services</a>,<br/>
  <a href="http://www.usa.gov/">USA.gov</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/copyright.html">Copyright</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/privacy.html">Privacy</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a>,&nbsp;
  <a href="http://www.nih.gov/icd/od/foia/index.htm">Freedom of Information Act</a><br/>

  <br/>
  <a href="http://www.nih.gov/"><img alt="U.S. National Institutes of Health" src="/ct2/html/images/frame/nih_logo.gif" border="0"/></a>
  <a href="http://www.nlm.nih.gov/"><img alt="U.S. National Library of Medicine" src="/ct2/html/images/frame/nlm_logo.gif" border="0"/></a>
  <a href="http://www.os.dhhs.gov/"><img alt="U.S. Department of Health &amp; Human Services" src="/ct2/html/images/frame/hhs_logo.gif" border="0"/></a>

  <br/>
  <br/>
  <br/>
  <br/>
  <a href="/ct2/crawl" class="skip">Links to all studies - primarily for crawlers</a>
</div>

<!-- 2010:04:05 01:58:55.751  RRf201T:SRf1Nxz:I4YaB4g -->
</body>
</html>
